| __timestamp | Amphastar Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 17986000 |
| Thursday, January 1, 2015 | 46974000 | 32480000 |
| Friday, January 1, 2016 | 47298000 | 68081000 |
| Sunday, January 1, 2017 | 50918000 | 169906000 |
| Monday, January 1, 2018 | 58044000 | 248932000 |
| Tuesday, January 1, 2019 | 63109000 | 354100000 |
| Wednesday, January 1, 2020 | 65157000 | 433300000 |
| Friday, January 1, 2021 | 68920000 | 583300000 |
| Saturday, January 1, 2022 | 66592000 | 752700000 |
| Sunday, January 1, 2023 | 80393000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, Amphastar Pharmaceuticals experienced a more modest growth of about 100% in the same timeframe. By 2023, Neurocrine's SG&A expenses were approximately 11 times higher than Amphastar's, highlighting a significant divergence in their financial strategies. This data provides a fascinating insight into how these companies allocate resources to support their operations and growth. Understanding these trends can offer valuable lessons for investors and industry analysts alike.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.